This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Heat shock protein 70 (Hsp70)	<p><i>In vitro</i> and mouse studies suggest that 2-phenylethynylsulfonamide (PES) inhibits Hsp70 and could help treat cancer. In cultured tumor cell lines, PES triggered cell death associated with protein aggregation and impairment of Hsp70-mediated autophagy. In a mouse model of lymphoma, the inhibitor decreased tumor development and increased survival compared with vehicle. Next steps include additional preclinical studies to confirm the function of the inhibitors.</p> <p>Multimmune GmbH's Enkastim, a synthetic Hsp-derived peptide targeting Hsp70, is in Phase I testing for colorectal and lung cancer. The company's mi-Tumex, a mAb against Hsp70, is in preclinical testing for cancer.</p> <p>SciBX 2(40); doi:10.1038/scibx.2009.1500 Published online Oct. 15, 2009</p>	Patent cooperation treaty patent application filed; available for licensing	<p>Leu, J. <i>et al. Mol. Cell.</i>; published online Oct. 8, 2009; doi:10.1016/j.molcel.2009.09.023</p> <p>Contact: Donna L. George, University of Pennsylvania School of Medicine, Philadelphia, Pa. e-mail: georged@mail.med.upenn.edu</p>